Health
Pfizer aims for $15bn in 2021 COVID-19 vaccine sales – PMLiVE
Current estimate is based on already agreed contracts
Pfizer has forecast major sales expectations for its BioNTech-partnered COVID-19 vaccine, BNT162b2, in its fourth quarter results – aiming for approximately $15bn in revenues for 2021.
The company said that the 2021 guidance for the vaccine mainly includes doses that are expected to be delivered in the year under existing contracts, adding that it may be adjusted dependent on future additional contracts.
In the fourth quarter of 2020 alone BNT162b2 contributed $154m to Pfizer’s overall sales.
For…
-
Noosa News22 hours agoRocky waters ahead for Brisbane 2032’s Olympic rowing plan
-
General24 hours agoEV buses join Perth’s wider suburban network, ‘milestone’ for diesel phase-out
-
Noosa News22 hours agoWoman loses arm in lion attack at Darling Downs Zoo in Queensland
-
General18 hours agoJordan Thompson retires from Wimbledon round-of-16 match with American Taylor Fritz